1-nitrohydroxyphenyl-n-benzoylalanine has been researched along with 2019 Novel Coronavirus Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alemohammad, SY; Behnoush, AH; Cannavo, A; Dimitroff, CJ; Kalantari, A; Khalaji, A | 1 |
| Arck, PC; Bayo, J; Blois, SM; Diemert, A; Dveksler, GS; Farhadian, SF; Garcia, MG; Kittmann, E; Lu-Culligan, A; Tallarek, AC; Urbschat, C; Vijayakumar, P; Wang, Y; Xie, Y; Zhao, F | 1 |
1 review(s) available for 1-nitrohydroxyphenyl-n-benzoylalanine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Galectins can serve as biomarkers in COVID-19: A comprehensive systematic review and meta-analysis.
Topics: Benzamides; Biomarkers; COVID-19; Galectins; Humans | 2023 |
1 other study(ies) available for 1-nitrohydroxyphenyl-n-benzoylalanine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
A unique maternal and placental galectin signature upon SARS-CoV-2 infection suggests galectin-1 as a key alarmin at the maternal-fetal interface.
Topics: Alarmins; COVID-19; Female; Galectin 1; Galectins; Humans; Infant, Newborn; Placenta; Pregnancy; SARS-CoV-2 | 2023 |